ContraVir Pharmaceuticals (NASDAQ:CTRV) announced a name change to Hepion Pharmaceuticals, and a stock symbol change to “HEPA,” effective as of opening of trading on July 23, 2019. “We derived the name “Hepion” by...
Intec Pharma (NASDAQ:NTEC) reported that its Accordion Pill carbidopa/levodopa (AP-CD/LD) failed to meet its primary endpoint in a Phase 3 trial for Parkinson’s disease (PD). Intec’s extended release AP-CD/LD failed to...
Theravance Biopharma (NASDAQ:TPBH) reported new data from its Phase 2 trial of ampreloxetine in patients with neurogenic orthostatic hypotension (nOH). nOH is characterized by a fall in systolic or diastolic blood...
PharmaCyte Biotech (OTCQB:PMCB) entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes, with the...
Zenabis Global (TSX:ZENA) entered into an agreement whereby Starseed Medicinal would advance $10-million to Zenabis in September 2019 in return for dried cannabis flower and trim from Zenabis. Under the accord, Zenabis...
Anavex Life Sciences (NASDAQ:AVXL) reported that Alzheimer’s disease (AD) patients with high levels of two gut microbiota families had an improved response to ANAVEX2-73. ANAVEX2-73 is an orally-administered liquid...
Aridis Pharmaceuticals (NASDAQ:ARDS) received European Medicines Agency (EMA) orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF). AR-501 is an inhaled...
InflaRx (NASDAQ:IFRX) reported that IFX-1 missed its primary endpoint in a Phase 2b trial in hidradenitis suppurativa (HS) patients. HS a chronic inflammatory skin disease that causes abscesses and scarring. IFX-1 is a...
Alphatec Holdings (NASDAQ:ATEC) launched its IdentiTi porous titanium interbody implant system for anterior lumbar interbody fusion procedures. Key features of the implant include a stiffness similar to bone, reduced...
BeyondSpring (NASDAQ:BYSI) priced a public offering of 2,058,825 ordinary shares at $17 apiece for expected gross proceeds of $35-million. The offering was led by Decheng Capital. The underwriter has a 30-day option to...